[{"id":"e1921994-65db-438f-afac-ccc5915b012d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06901908","created_at":"2025-07-19T14:06:19.418Z","updated_at":"2025-07-19T14:06:19.418Z","phase":"","brief_title":"Role of Cytomorphometry and BRAFV600E Immunocytochemistry With a Cytologic Diagnosis \"Suspicious for Papillary Thyroid Carcinoma\"","source_id_and_acronym":"NCT06901908","lead_sponsor":"Assiut University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-04-03"},{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"0a783bcc-4ad7-4844-9ff8-1c57f587c024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04759911","created_at":"2021-02-18T22:55:11.009Z","updated_at":"2025-02-25T16:53:32.021Z","phase":"Phase 2","brief_title":"Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer","source_id_and_acronym":"NCT04759911","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/26/2021","start_date":" 02/26/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-04"},{"id":"9757c252-7155-4955-97b3-9b0dca727693","acronym":"ENBolden-101","url":"https://clinicaltrials.gov/study/NCT04205227","created_at":"2021-01-18T20:29:07.147Z","updated_at":"2025-02-25T16:09:46.047Z","phase":"Phase 1/2","brief_title":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","source_id_and_acronym":"NCT04205227 - ENBolden-101","lead_sponsor":"ENB Therapeutics, Inc","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ENB003"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/18/2020","start_date":" 02/18/2020","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-09-19"},{"id":"2370ef8d-6eee-4c58-9934-7a91c5f352f0","acronym":"NePenThe","url":"https://clinicaltrials.gov/study/NCT05852223","created_at":"2023-05-10T21:03:54.092Z","updated_at":"2025-02-25T16:18:46.649Z","phase":"Phase 2","brief_title":"Pembrolizumab in High-risk Thyroid Cancer","source_id_and_acronym":"NCT05852223 - NePenThe","lead_sponsor":"Istituti Clinici Scientifici Maugeri SpA","biomarkers":" BRAF • CD8","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-07-09"},{"id":"897d9629-7c12-4d49-92b0-10b4a3de5a1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02973997","created_at":"2025-02-26T08:59:58.704Z","updated_at":"2025-02-26T08:59:58.704Z","phase":"Phase 2","brief_title":"Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)","source_id_and_acronym":"NCT02973997","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CD8 • PD-L2","pipe":"","alterations":" ","tags":["CD8 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 10/08/2023","study_completion_date":" 10/08/2023","last_update_posted":"2024-07-01"},{"id":"ad64e5d0-95d3-4f41-a430-f89469610dd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914300","created_at":"2023-12-06T21:16:15.541Z","updated_at":"2024-07-02T16:34:26.125Z","phase":"Phase 2","brief_title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03914300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-06-14"},{"id":"7ee65b79-49ff-449c-ae18-0e2f8ded36d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06440850","created_at":"2024-06-08T04:18:06.782Z","updated_at":"2024-07-02T16:34:59.043Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","source_id_and_acronym":"NCT06440850","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-04"},{"id":"d8059b4f-3b03-40aa-8b9b-b4fdbc881145","acronym":"","url":"https://clinicaltrials.gov/study/NCT01709292","created_at":"2021-01-18T07:26:46.450Z","updated_at":"2024-07-02T16:35:02.453Z","phase":"Phase 2","brief_title":"Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer","source_id_and_acronym":"NCT01709292","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/07/2012","start_date":" 11/07/2012","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-05-21"},{"id":"7b6ebe70-800e-4560-80b6-cf916fe1b220","acronym":"MAPS","url":"https://clinicaltrials.gov/study/NCT06235814","created_at":"2024-02-01T15:20:05.141Z","updated_at":"2024-07-02T16:35:04.220Z","phase":"","brief_title":"Molecular Analysis for Precision Surgery in Thyroid Cancer Trial","source_id_and_acronym":"NCT06235814 - MAPS","lead_sponsor":"University of California, Los Angeles","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 07/30/2024","start_date":" 07/30/2024","primary_txt":" Primary completion: 04/08/2026","primary_completion_date":" 04/08/2026","study_txt":" Completion: 04/08/2026","study_completion_date":" 04/08/2026","last_update_posted":"2024-05-13"},{"id":"b6b2754e-5306-4023-a3e5-75d3f7fe5848","acronym":"","url":"https://clinicaltrials.gov/study/NCT05620134","created_at":"2022-11-17T14:57:00.380Z","updated_at":"2024-07-02T16:35:08.649Z","phase":"Phase 1/2","brief_title":"Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer","source_id_and_acronym":"NCT05620134","lead_sponsor":"Salubris Biotherapeutics Inc","biomarkers":" HER-2 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["HER-2 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SAL008"],"overall_status":"Recruiting","enrollment":" Enrollment 263","initiation":"Initiation: 10/17/2022","start_date":" 10/17/2022","primary_txt":" Primary completion: 10/17/2025","primary_completion_date":" 10/17/2025","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2024-04-19"},{"id":"a8cefe5a-e94b-46ed-9583-4ada655fa885","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT03470259","created_at":"2021-01-18T17:06:10.081Z","updated_at":"2024-07-02T16:35:09.398Z","phase":"Phase 1","brief_title":"Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging","source_id_and_acronym":"NCT03470259 - TARGET","lead_sponsor":"University Medical Center Groningen","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2024-04-16"},{"id":"592ebddd-dcd6-4b4f-ad61-a8f732fba350","acronym":"ARROW","url":"https://clinicaltrials.gov/study/NCT03037385","created_at":"2021-01-17T17:13:27.011Z","updated_at":"2024-07-02T16:35:10.042Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","source_id_and_acronym":"NCT03037385 - ARROW","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation • RET rearrangement","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 589","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 03/21/2024","primary_completion_date":" 03/21/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-11"},{"id":"cb8d2781-175e-47d3-a3e8-c2f88771d5b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381641","created_at":"2023-11-22T18:15:18.641Z","updated_at":"2024-07-02T16:35:11.050Z","phase":"Phase 2","brief_title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00381641","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/08/2006","start_date":" 08/08/2006","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2024-04-08"},{"id":"8fc7055a-dde1-4071-9f3b-d016eed452de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04891198","created_at":"2021-05-18T12:02:07.091Z","updated_at":"2024-07-02T16:35:11.517Z","phase":"Phase 2","brief_title":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04891198","lead_sponsor":"3D Medicines (Sichuan) Co., Ltd.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-04-03"},{"id":"f8142c0b-7e40-45b9-aed0-5a10b17b3a25","acronym":"FIRELIGHT-1","url":"https://clinicaltrials.gov/study/NCT04985604","created_at":"2023-06-26T16:09:30.280Z","updated_at":"2024-07-02T16:35:12.349Z","phase":"Phase 1/2","brief_title":"Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT04985604 - FIRELIGHT-1","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF • NF1 • RAF1","pipe":" | ","alterations":" BRAF fusion • RAF1 amplification","tags":["BRAF • NF1 • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF fusion • RAF1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • pimasertib (AS703026)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-29"},{"id":"8214fea8-a403-48c1-9fa6-030636cc99e1","acronym":"STARTRK-2","url":"https://clinicaltrials.gov/study/NCT02568267","created_at":"2021-01-17T17:20:53.382Z","updated_at":"2024-07-02T16:35:12.401Z","phase":"Phase 2","brief_title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","source_id_and_acronym":"NCT02568267 - STARTRK-2","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 534","initiation":"Initiation: 11/19/2015","start_date":" 11/19/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-28"},{"id":"5ae46888-f8b0-440f-bff1-4bb38bf3e79f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03488134","created_at":"2021-01-18T17:10:46.745Z","updated_at":"2024-07-02T16:35:13.946Z","phase":"","brief_title":"Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3","source_id_and_acronym":"NCT03488134","lead_sponsor":"National Taiwan University Hospital","biomarkers":" KRT8","pipe":"","alterations":" ","tags":["KRT8"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 08/03/2018","start_date":" 08/03/2018","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 02/20/2024","study_completion_date":" 02/20/2024","last_update_posted":"2024-03-19"},{"id":"5c9414e8-7220-42f4-8441-a2cd65e87bf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463107","created_at":"2022-07-18T14:01:53.359Z","updated_at":"2024-07-02T16:35:14.098Z","phase":"","brief_title":"Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer","source_id_and_acronym":"NCT05463107","lead_sponsor":"National Taiwan University Hospital","biomarkers":" KRT19 • KRT8 • TG","pipe":"","alterations":" ","tags":["KRT19 • KRT8 • TG"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-03-19"},{"id":"0b6e5ad5-c4b9-4e11-ac82-4f01f7ab9b5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04834778","created_at":"2021-04-08T13:52:24.698Z","updated_at":"2024-07-02T16:35:15.757Z","phase":"Phase 1","brief_title":"A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)","source_id_and_acronym":"NCT04834778","lead_sponsor":"HiberCell, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HC-5404"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 12/07/2023","primary_completion_date":" 12/07/2023","study_txt":" Completion: 01/30/2024","study_completion_date":" 01/30/2024","last_update_posted":"2024-03-08"},{"id":"cbadcf07-a7e7-4ec4-b497-346814eb3bc4","acronym":"LIBRETTO-121","url":"https://clinicaltrials.gov/study/NCT03899792","created_at":"2021-01-18T19:12:12.872Z","updated_at":"2024-07-02T16:35:15.915Z","phase":"Phase 1/2","brief_title":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","source_id_and_acronym":"NCT03899792 - LIBRETTO-121","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/13/2019","start_date":" 06/13/2019","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2024-03-07"},{"id":"af734147-b4c2-4351-87af-14a4c5e4f2fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04462471","created_at":"2021-01-18T21:27:12.136Z","updated_at":"2024-07-02T16:35:17.410Z","phase":"Phase 1","brief_title":"Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers","source_id_and_acronym":"NCT04462471","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/26/2020","start_date":" 06/26/2020","primary_txt":" Primary completion: 09/29/2023","primary_completion_date":" 09/29/2023","study_txt":" Completion: 09/29/2023","study_completion_date":" 09/29/2023","last_update_posted":"2024-02-28"},{"id":"cd334664-b55d-49f3-960b-50fed3f6d9ca","acronym":" AcSé Pembrolizumab study","url":"https://clinicaltrials.gov/study/NCT03012620","created_at":"2021-01-18T14:49:27.880Z","updated_at":"2025-02-25T16:05:41.112Z","phase":"Phase 2","brief_title":"Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types","source_id_and_acronym":"NCT03012620 -  AcSé Pembrolizumab study","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":" | ","alterations":" PD-L1 underexpression • FASN-L","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 underexpression • FASN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 12/26/2022","primary_completion_date":" 12/26/2022","study_txt":" Completion: 12/14/2023","study_completion_date":" 12/14/2023","last_update_posted":"2024-02-28"}]